


WHAT IS CLAIMED IS:

1. A compound of Formula (I):



or a pharmaceutically acceptable salt or solvate thereof, wherein:

Y is O or S;

X¹ is hydrogen, fluoro or chloro;

X² is hydrogen, fluoro or chloro;

R^{3a} is hydrogen, fluoro, chloro, cyano, C₁₋₃haloalkyl, C₁₋₃alkoxy or C₁₋₃haloalkoxy;

R^{3b} is hydrogen, fluoro, chloro, cyano or C₁₋₃haloalkyl;

R^{3c} is hydrogen, fluoro or chloro;

R^{3d} is hydrogen, fluoro or chloro;


R¹⁰ is C₁₋₃alkyl, C₃₋₄cycloalkyl or C₃₋₄cycloalkylC₁₋₃alkyl;

provided (i) when R^{3b} is fluoro, R^{3a} is methoxy and R^{3c} and R^{3d} are each hydrogen, or (ii) when R^{3b} is hydrogen, R^{3a} is isopropoxy and R^{3c} and R^{3d} are each hydrogen, or (iii) when R^{3a}, R^{3b}, R^{3c} and R^{3d} are all hydrogen, then at least one of X¹ and X² is fluoro or chloro; and provided, when R^{3a} is CF₃, R^{3b} is fluoro, and R^{3c} and R^{3d} are each hydrogen, then R¹⁰ is not cyclopropylmethyl.

2. The compound of claim 1, wherein R^{3a} is hydrogen, fluoro, chloro, cyano, C₁₋₃haloalkyl, C₁₋₃alkoxy or C₁₋₃haloalkoxy; R^{3b} is fluoro or chloro, R^{3c} is hydrogen, fluoro or chloro and R^{3d} is hydrogen.

3. The compound of claim 1 or 2, wherein R^{3a} is hydrogen, fluoro, chloro, cyano, C₁₋₃haloalkyl, C₁₋₃alkoxy or C₁₋₃haloalkoxy; R^{3b} is fluoro or chloro; R^{3c} and R^{3d} are each hydrogen.

4. The compound of any one of claims 1 to 3, wherein R^{3b} is fluoro or chloro and R^{3a} , R^{3c} and R^{3d} are each hydrogen.
5. The compound of claim 1, wherein one of R^{3a} , R^{3b} , R^{3c} and R^{3d} is fluoro, chloro or cyano and the remainder of R^{3a} , R^{3b} , R^{3c} and R^{3d} are each hydrogen.
6. The compound of claim 1, wherein one of R^{3a} and R^{3b} is fluoro, chloro, cyano or C_{1-3} alkoxy; the other of R^{3a} and R^{3b} is fluoro or hydrogen; and R^{3c} and R^{3d} are each hydrogen.
7. The compound of claim 1, wherein (i) R^{3a} is fluoro or cyano; and R^{3b} , R^{3c} and R^{3d} are each hydrogen or (ii) R^{3a} is hydrogen, chloro or C_{1-3} alkoxy; R^{3b} is fluoro or cyano; and R^{3c} and R^{3d} are each hydrogen.
8. The compound of claim 1 or 2, having the Formula (Ia):



or a pharmaceutically acceptable salt or solvate thereof wherein:

Y is O or S;

X^1 is hydrogen, fluoro or chloro;

X^2 is hydrogen, fluoro or chloro;


R^{3a} is hydrogen, fluoro, chloro, cyano, C_{1-3} haloalkyl, C_{1-3} alkoxy or C_{1-3} haloalkoxy;

R^{3c} is hydrogen or fluoro; and

R^{10} is C_{1-3} alkyl, C_{3-4} cycloalkyl or C_{3-4} cycloalkyl C_{1-3} alkyl;

provided when R^{3a} is methoxy and R^{3c} is hydrogen, then at least one of X^1 and X^2 is fluoro or chloro; and provided, when R^{3a} is CF_3 , and R^{3c} is hydrogen, then R^{10} is not cyclopropylmethyl.

9. The compound of any one of claims 1 to 3, having the Formula (Ib):




(Ib),

or a pharmaceutically acceptable salt or solvate thereof,

wherein Y, R^{3a}, R¹⁰, X¹ and X² are as described above.


10. The compound of any one of claims 1 to 5, having the Formula (Ic):





(Ic),


or a pharmaceutically acceptable salt or solvate thereof, wherein Y, R¹⁰, X¹ and X² are as described above.

11. The compound of any one of claims 1 to 9, wherein R^{3a} is hydrogen, fluoro, chloro, cyano, C₁₋₃alkoxy or C₁₋₃haloalkoxy.
12. The compound of any one of claims 1 to 11, wherein Y is S.
13. The compound of any one of claims 1 to 12, wherein R¹⁰ is C₃₋₄cycloalkylC₁₋₃alkyl.
14. The compound of any one of claims 1 to 13, wherein R¹⁰ is cyclopropylmethyl.
15. The compound of any one of claims 1 to 14, wherein X¹ is fluoro or chloro.
16. The compound of claim 1, selected from:










or a pharmaceutically acceptable salt or solvate thereof.

17. A compound of Formula (II):



or a pharmaceutically acceptable salt or solvate thereof, wherein:

X¹ is hydrogen, fluoro or chloro;

X² is hydrogen, fluoro or chloro;


R^{3a} is fluoro, chloro, cyano, C₁₋₃haloalkyl, C₁₋₃alkoxy or C₁₋₃haloalkoxy;

R^{3c} is hydrogen, fluoro or chloro; and

R¹⁰ is C₁₋₃alkyl, C₃₋₄cycloalkyl or C₃₋₄cycloalkylC₁₋₃alkyl.

18. The compound of claim 17, wherein R^{3a} is fluoro or chloro and R^{3c} is fluoro or chloro.

19. The compound of claim 17 or 18, having the Formula (IIa):



or a pharmaceutically acceptable salt or solvate thereof;

wherein R^{3a}, R¹⁰, X¹ and X² are as described above.

20. The compound of any one of claims 17 to 19, wherein R^{3a} is fluoro or chloro.

21. The compound of any one of claims 17 to 20, wherein X¹ is fluoro or chloro.

22. The compound of any one of claims 17 to 21, wherein X¹ is fluoro or chloro and X² is hydrogen.

23. The compound of any one of claims 1 to 22, wherein the compound is present in the form of a pharmaceutically acceptable salt.

24. The compound of any one of claims 1 to 22, wherein the compound is present in the form of a solvate.

25. The compound of claim 24, wherein the solvate is a hydrate.

26. A pharmaceutical composition comprising a compound of any one of claims 1 to 25 and a pharmaceutically acceptable carrier.

27. A method of treating a disease or disorder associated with elevated oxalate levels, comprising administering to a subject having such disease or disorder, a therapeutically

effective amount of a compound of any one of claims 1 to 25, or a pharmaceutical composition of claim 26.

28. The method of claim 27, wherein the elevated oxalate levels is elevated urinary oxalate levels.

29. The method of claim 27, wherein the elevated oxalate levels is elevated plasma oxalate levels.

30. The method of any one of claims 27 to 29, wherein the disease or disorder is hyperoxaluria, chronic kidney disease (CKD), end stage renal disease (ESRD) or kidney stone disease.

31. The method of claim 30, wherein the hyperoxaluria is primary hyperoxaluria or secondary hyperoxaluria.

32. The method of claim 31, wherein the primary hyperoxaluria is primary hyperoxaluria type 1 (PH-1), primary hyperoxaluria type 2 (PH-2) or primary hyperoxaluria type 3 (PH-3).

33. The method of any one of claims 27 to 32, wherein the subject with the disease or disorder has an *AGXT*, *GRHPR* or *HOGA1* mutation, or a combination of mutations thereof.

34. A method of lowering oxalate levels in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 25, or a pharmaceutical composition of claim 26.

35. A method of treating kidney stone formation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound any one of claims 1 to 25, or a pharmaceutical composition of claim 26.

36. The method of any one of claims 27 to 35, further comprising administering to the subject a therapeutically effective amount of a second therapeutic agent.

37. The method of claim 36, wherein the second therapeutic agent is a glyoxylate or oxalate lowering therapeutic.

38. The method of claim 37, wherein the glyoxylate or oxalate lowering therapeutic is an RNAi therapeutic.

39. The method of claim 37, wherein the glyoxylate or oxalate lowering therapeutic is lumasiran, nedosiran, reloxaliase, stiripentol, oxalobacter formigenes or vitamin B6.

40. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition of claim 26, for use in treating a disease or disorder associated with elevated oxalate levels.

41. The compound of any one claims 1 to 25, or a pharmaceutically acceptable salt or solvate thereof, for use in claim 40, wherein the disease or disorder is hyperoxaluria, chronic kidney disease (CKD), end stage renal disease (ESRD) or kidney stone disease.

42. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt or solvate thereof, for use in claim 41, wherein the hyperoxaluria is primary hyperoxaluria or secondary hyperoxaluria.

43. The compound of any one of claims 1 to 25, or a pharmaceutically acceptable salt or solvate thereof, for use in claim 40, wherein the disease or disorder is associated with an *AGXT*, *GRHPR* or *HOGAI* mutation, or a combination of mutations thereof.